Glenmark Pharmaceuticals Ltd Quarterly Results
Q4 FY25-26 Results Summary
Revenue
The revenue stands at ₹3,770.59 crore, reflecting a quarter-on-quarter *(QoQ) decrease of 3.33 per cent from ₹3,900.62 crore. This corresponds to a year-on-year *(YoY) growth of 15.80 per cent.
Operating Profit
Operating Profit stands at ₹389.20 crore, reflecting a quarter-on-quarter *(QoQ) decrease of 43.22 per cent from ₹685.42 crore. This corresponds to a year-on-year *(YoY) growth of 106.80 per cent.
PBDT
PBDT stands at ₹535.67 crore, reflecting a quarter-on-quarter *(QoQ) decrease of 22.19 per cent from ₹688.45 crore. This corresponds to a year-on-year *(YoY) growth of 302.22 per cent.
Profit Before Tax
Profit Before Tax stands at ₹387.76 crore, reflecting a quarter-on-quarter *(QoQ) decrease of 27.39 per cent from ₹534.00 crore. This corresponds to a year-on-year *(YoY) growth of 4,765.24 per cent.
Net Profit
Net Profit stands at ₹301.31 crore, reflecting a quarter-on-quarter *(QoQ) decrease of 25.28 per cent from ₹403.23 crore. This represents a 6,779.22 per cent year-on-year *(YoY) growth for the same year.
- YoY compares a quarter to the same period last year, and QoQ compares it to the previous quarter.
Glenmark Pharmaceuticals Ltd News
Glenmark Pharmaceuticals Ltd Earnings
- YOY
- QOQ
Glenmark Pharmaceuticals Ltd Earning Charts
Revenue from Operations
in ₹ cr
EBITDA
in ₹ cr
Profit before Tax
in ₹ cr
Net Profit
in ₹ cr
Glenmark Pharmaceuticals Ltd Research Reports
Glenmark Pharmaceuticals Ltd Financial Reports
Glenmark Pharmaceuticals Ltd Stock Prices Compare with Peers
| Company | 1 Day | 1 Week | 1 month | 3 month | 6 month | 1 Year |
|---|---|---|---|---|---|---|
| Glenmark Pharma. | -0.81% | -1.62% | -8.67% | 2.30% | 12.84% | 35.47% |
| Laurus Labs | 1.19% | 4.22% | 19.94% | 41.74% | 44.12% | 116.91% |
| Biocon | -1.18% | -3.16% | 7.70% | 5.71% | 7.29% | 21.87% |
| Alkem Lab | -0.40% | -1.24% | -6.07% | -3.83% | -6.22% | 7.73% |
| Abbott India | 0.45% | -2.83% | -2.53% | -4.20% | -9.09% | -18.22% |
| Anthem Bioscienc | 2.04% | 0.87% | -2.18% | 15.45% | 17.56% | 4.33% |
| Ipca Labs. | 1.66% | 9.90% | 5.47% | 9.07% | 13.35% | 20.05% |
Company Info
Company Information
Chairman / Executive Director / M D / Promoter : Glenn Saldanha
ED / WTD / Promoter : Cheryl Pinto
ED / President / Global CFO : Anurag Mantri
Non Executive Director : B E Saldanha
Independent Non Exe. Director : Sona Saira Ramasastry
Independent Non Exe. Director : Dipankar Bhattacharjee
Independent Non Exe. Director : V R Iyer
Independent Non Exe. Director : Pradeep Kumar Sinha
Company Sec. & Compli. Officer : Harish Kuber